The results revealed that APOE ε4 allele non-carriers showed stronger anti-AD effects and that PPARγ genetic variation may alter the risk of AD occurrence in an APOE ε4 allele-dependent manner [127,128]. The gene discussed is APOE; the disease is Alzheimer disease.